TY - JOUR
T1 - Increased anti-KIR4.1 antibodies in multiple sclerosis
T2 - could it be a marker of disease relapse?
AU - Brill, Livnat
AU - Goldberg, Lotem
AU - Karni, Arnon
AU - Petrou, Panayiota
AU - Abramsky, Oded
AU - Ovadia, Haim
AU - Ben-Hur, Tamir
AU - Karussis, Dimitrios
AU - Vaknin-Dembinsky, Adi
N1 - Publisher Copyright:
© The Author(s), 2014.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - BACKGROUND: Screening of putative autoimmune targets in multiple sclerosis (MS) revealed a proportion of patients carrying antibodies (Abs) against KIR4.1, a potassium channel that shares functional properties with AQP4. Both are localized at the perivascular astrocytic processes.AIMS: To measure anti-KIR4.1 Abs in the serum of MS and neuromyelitis optica (NMO) patients, and to identify the clinical and laboratory characteristics of patients harboring anti-KIR4.1 Abs.METHODS: We measured anti-KIR4.1 Abs in serum, using the peptide KIR4.1 (83-120) enzyme-linked immunosorbent assay (ELISA).RESULTS: Serum levels of anti-KIR4.1 Abs were significantly higher in MS and NMO patients than in healthy controls (HCs); with Abs detected in 21 of 80, 10 of 45, and 2 of 32 individuals, respectively (MS versus HC, p < 0.05). The level of anti-KIR4.1 Abs was significantly higher during MS relapse, versus remission (p = 0.04). The clinical characteristics of our study patients did not vary based on KIR4.1 positivity.CONCLUSIONS: Anti-KIR4.1 Abs were found in similar proportions of patients with MS and NMO, at a significantly higher level than observed in HCs; consequently, the presence of Abs does not discriminate between these demyelinating diseases. However, anti-KIR4.1 Ab levels differed in MS patients during relapse and remission; as such, they may represent a marker of disease exacerbation.
AB - BACKGROUND: Screening of putative autoimmune targets in multiple sclerosis (MS) revealed a proportion of patients carrying antibodies (Abs) against KIR4.1, a potassium channel that shares functional properties with AQP4. Both are localized at the perivascular astrocytic processes.AIMS: To measure anti-KIR4.1 Abs in the serum of MS and neuromyelitis optica (NMO) patients, and to identify the clinical and laboratory characteristics of patients harboring anti-KIR4.1 Abs.METHODS: We measured anti-KIR4.1 Abs in serum, using the peptide KIR4.1 (83-120) enzyme-linked immunosorbent assay (ELISA).RESULTS: Serum levels of anti-KIR4.1 Abs were significantly higher in MS and NMO patients than in healthy controls (HCs); with Abs detected in 21 of 80, 10 of 45, and 2 of 32 individuals, respectively (MS versus HC, p < 0.05). The level of anti-KIR4.1 Abs was significantly higher during MS relapse, versus remission (p = 0.04). The clinical characteristics of our study patients did not vary based on KIR4.1 positivity.CONCLUSIONS: Anti-KIR4.1 Abs were found in similar proportions of patients with MS and NMO, at a significantly higher level than observed in HCs; consequently, the presence of Abs does not discriminate between these demyelinating diseases. However, anti-KIR4.1 Ab levels differed in MS patients during relapse and remission; as such, they may represent a marker of disease exacerbation.
KW - Autoimmune disease
KW - KIR4.1
KW - biomarker
KW - immunoassay
KW - immunology
KW - multiple sclerosis
KW - neuromyelitis optica
KW - potassium channel
KW - relapse
UR - http://www.scopus.com/inward/record.url?scp=84952784463&partnerID=8YFLogxK
U2 - 10.1177/1352458514551779
DO - 10.1177/1352458514551779
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 25392324
AN - SCOPUS:84952784463
SN - 1352-4585
VL - 21
SP - 572
EP - 579
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
IS - 5
ER -